Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

466.22 -12.35 (-2.58%)
Streaming Delayed Price Updated: 1:35 PM EDT, Sep 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
51 52 Next >
The Best Stocks to Invest $20,000 in Right Now
These businesses are already strong, but they could grow much larger. 
Via The Motley Fool
3 Monster Stocks to Buy Without Any Hesitation
These stocks are monsters now. They'll probably be much bigger monsters over the next decade and beyond. 
Via The Motley Fool
3 Surefire Stocks That Can Thrive During a Recession
These time-tested businesses have the sustainable cash flow and catalysts needed to outperform when the U.S. economy isn't at its best. 
Via The Motley Fool
12-Stock Portfolio -- 25 Growth Stocks to Buy Now
If I were starting a new growth stock portfolio today, here are the stocks I'd buy. 
Via The Motley Fool
2 Explosive Stocks That Could Go Parabolic
Don't let these stocks pass you by when you go shopping for more wonderful businesses. 
Via The Motley Fool
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest
Via Benzinga
Worried About the Banking Turmoil? These 3 Stocks Shouldn't Skip a Beat
Investors can sleep peacefully owning these stocks. 
Via The Motley Fool
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
The best pharma stocks to buy are those that are poised to be greatly boosted by drugs that are well-positioned to become blockbusters. 
Via InvestorPlace
Exelixis Stock Generating Improved Relative Strength Rating
Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76. 
Via Investor's Business Daily
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
2 Top Biotech Stocks to Buy for the Long Haul
These companies have what it takes to grow their revenues -- and their share prices -- over time. 
Via The Motley Fool
Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade
Vertex Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 67 to 77. 
Via Investor's Business Daily
Prediction: These 3 Stocks Will Be in the Dow by 2030
Being added to the Dow Jones Industrial Average would just be another feather in the cap for these successful stocks. 
Via The Motley Fool
3 Supercharged Stocks With More Potential Than Any Cryptocurrency
These growth stocks are going from strength to strength. 
Via The Motley Fool
This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a Buy
The company's future in the stock market could look very much like its past. 
Via The Motley Fool
2 Top Stocks to Buy in March and Hold Forever
Don't let a turbulent market keep you on the sidelines this month. 
Via The Motley Fool
Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold
Get in on CRISPR Therapeutics before it gets expensive. 
Via The Motley Fool
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
4 Growth Stocks to Buy and Hold Forever
These stocks have what it takes to achieve long-term success. 
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy Right Now
These companies have what it takes to survive and thrive beyond the next bear market. 
Via The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022. 
Via InvestorPlace
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on. 
Via InvestorPlace
3 Things About CRISPR Therapeutics That Smart Investors Know
Institutional investors might be on to something. 
Via The Motley Fool
3 Game-Changing Stocks to Buy in March
Innovation is in these companies' DNA. 
Via The Motley Fool
Prediction: These 3 S&P 500 Stocks Will at Least Double in 7 Years
These large-cap stocks should grow much larger. 
Via The Motley Fool
2 Growth Stocks to Invest $1,000 in Right Now
Both of these biopharmas have major catalysts that are in play or drawing near. 
Via The Motley Fool
3 Nasdaq 100 Stocks to Buy Hand Over Fist in March
The predominantly growth-oriented Nasdaq 100 is home to three amazing deals hiding in plain sight. 
Via The Motley Fool
3 Incredible Growth Stocks to Buy if the Market Dips
These top growth stocks sport premium valuations for a very good reason. 
Via The Motley Fool
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
51 52 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.